Evidence map›Paper›PMID 23533266›Full record

ArticleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2013

Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statistics.

Pieter G Postema, Jon Neville, Jonas S S G de Jong, Klaus Romero, Arthur A M Wilde, Raymond L Woosley

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Clinical profile and prognosis of brugada syndrome SCN5A variant carriers with negative sodium channel blocker challenge.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  4. Further mystification of SCN5A phenotypes: sodium channel blockade in individuals with loss-of-function sodium channel mutations dangerous or helpful?Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  5. Review
  6. Diagnosing Brugada syndrome: look for right ventricular outflow tract conduction delay.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Article
  7. Accumulating evidence for epicardial ablation in malignant forms of Brugada syndrome: summary of two randomized clinical trials.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Article
  8. Article
  9. A heart job: predicting sudden cardiac arrest.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Article
  10. Review
  11. The psychological impact of receiving a Brugada syndrome diagnosis.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Article
  12. Article
  13. Severity of Brugada syndrome disease manifestation and risk of new-onset depression or anxiety: a Danish nationwide study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. Multiple categories of non-cardiac QT-prolonging drugs are associated with increased risk of out-of-hospital cardiac arrest: real-world data from a population-based study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2022
    Article
  18. Novel presentation ofHeartRhythm case reports · 2022
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Pieter G PostemaDepartment of Cardiology, Heart Center, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. P.G.Postema@cardiologie-amc.nl
Jon Neville
Jonas S S G de Jong
Klaus Romero
Arthur A M Wilde
Raymond L Woosley
Arizona Department of Education · USAcademic Medical Center · NLCritical Path Institute · USHersenstichting · NLUniversity of Amsterdam · NL

Funding

CENTER FOR EDUCATION AND RESEARCH ON THERAPEUTICSU18HS010385 · AHRQ · UNIVERSITY OF ARIZONA · PI WOOSLEY, RAYMOND L · 1999 to 2006
$621k
AHRQ HHS U18 HS010385
6 · The paper itself

Abstract

aimsWe sought to obtain insights into the efficacy of two websites, www.QTdrugs.org and www.BrugadaDrugs.org, that have the intention to prevent fatal arrhythmias due to unsafe drug use in Long QT syndrome and Brugada syndrome. METHODS AND

resultsProspective web-use statistical analysis combined with online surveys were employed. Our main outcome measure was the percentage of Long QT syndrome patients and Brugada syndrome patients reporting refraining or discontinuation of possible unsafe drugs. QTdrugs.org has received >3 100 000 visitors from 180 countries. Most visitors originated from the Americas (87%), as compared with Europe (7%), Asia (3%), Oceania (2%), and Africa (1%). The QTdrugs.org survey yielded 340 respondents: 34% were patients and 50% medical professionals. Of the patients, 79% reported that they refrained from, and 61% reported discontinuing drugs due to the website. The website was very much appreciated by 65% of the respondents and 30% found it rather helpful. The BrugadaDrugs.org received >48 000 visitors from 154 countries. Most visitors originated from Europe (46%) and the Americas (39%), but less from Asia (10%), Oceania (4%), and Africa (<1%). The BrugadaDrugs.org survey yielded 178 respondents: 68% were patients and 21% medical professionals. Of the patients, 72% reported refraining from, and 48% discontinuing drugs due to the website. The website was very much appreciated by 72% of the respondents and 25% found it rather helpful.

conclusionThese websites are extensively used, they promote drug awareness, and they help patients to avoid possible pro-arrhythmic drugs. Visitors find the websites valuable but should note their limitations.

Indexed as

AdultBrugada SyndromeDeath, Sudden, CardiacDrug Information ServicesDrug-Related Side Effects and Adverse ReactionsFemaleHealth Knowledge, Attitudes, PracticeHumansInternetLong QT SyndromeMaleMiddle AgedPatient Education as TopicProspective StudiesRisk FactorsSurveys and QuestionnairesBrugada syndromeCardiac arrestDrugsLong QT syndromeSide effectswebsite statisticswebsite use

Identifiers

PMID23533266
PMCPMC3857912
OpenAlexW2118884587

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.